Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6039 |
| Name | uveal melanoma |
| Definition | A uveal cancer that has_material_basis_in uvea pigment cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer sensory system cancer ocular cancer uveal cancer uveal melanoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | YM-254890 | uveal melanoma | no benefit | detail... |
| NRAS Q61K | YM-254890 | uveal melanoma | no benefit | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00489944 | Phase II | Cisplatin + Sunitinib + Tamoxifen | Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma | Unknown status | USA | 0 |
| NCT01200238 | Phase II | Ganetespib | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | Completed | USA | 0 |
| NCT01430416 | Phase I | Sotrastaurin | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | Completed | USA | NLD | GBR | FRA | 0 |
| NCT01471054 | Phase II | Dexamethasone intravitreal implant Bevacizumab | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | Terminated | USA | 0 |
| NCT01585194 | Phase II | Ipilimumab Nivolumab | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Completed | USA | 0 |
| NCT01587352 | Phase II | Vorinostat | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | Active, not recruiting | USA | 0 |
| NCT01835145 | Phase II | Dacarbazine Temozolomide Cabozantinib | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye | Completed | USA | CAN | 0 |
| NCT01974752 | Phase III | Dacarbazine + Selumetinib | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | Completed | USA | NLD | ISR | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BEL | 0 |
| NCT01979523 | Phase II | Trametinib Trametinib + Uprosertib | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | GBR | FRA | 0 |
| NCT02068586 | Phase II | Valproic acid Sunitinib | Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT02223819 | Phase II | Crizotinib | Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | Completed | USA | 0 |
| NCT02273219 | Phase I | Alpelisib + Sotrastaurin | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Completed | USA | 0 |
| NCT02359851 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | Terminated | USA | 0 |
| NCT02363283 | Phase II | Glembatumumab vedotin | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | Completed | USA | 0 |
| NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT02570308 | Phase I | Tebentafusp | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | Completed | USA | GBR | ESP | DEU | CAN | 0 |
| NCT02601378 | Phase I | IDE196 + Siremadlin IDE196 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | Terminated | USA | NOR | NLD | FRA | ESP | AUS | 0 |
| NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Active, not recruiting | AUS | 0 |
| NCT02768766 | Phase I | Selumetinib | Intermittent Selumetinib for Uveal Melanoma | Completed | USA | 0 |
| NCT02913417 | Phase Ib/II | Ipilimumab + Nivolumab + Yttrium-90 microsphere therapy | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | Unknown status | USA | 0 |
| NCT03022565 | Phase I | Vorinostat | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | Withdrawn | 0 | |
| NCT03052127 | Phase I | AU-011 | Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma | Completed | USA | 0 |
| NCT03068624 | Phase I | Aldesleukin + Cyclophosphamide + Ipilimumab | Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT03070392 | Phase II | Dacarbazine Ipilimumab Pembrolizumab Tebentafusp | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
| NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
| NCT03408587 | Phase I | Coxsackievirus A21 + Ipilimumab | CAVATAK and Ipilimumab in Uveal Melanoma Metastatic to the LIver (VLA-024 CLEVER) (CLEVER) | Completed | USA | 0 |
| NCT03417739 | Phase II | Ulixertinib | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
| NCT03686124 | Phase Ib/II | IMA-203 | ACTengine IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine) | Recruiting | USA | DEU | 0 |
| NCT03712904 | Phase II | Aflibercept | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | Terminated | USA | 0 |
| NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
| NCT03746431 | Phase Ib/II | 225Ac-FPI-1434 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Active, not recruiting | USA | CAN | AUS | 0 |
| NCT03922880 | Phase I | ADI-PEG 20 + Ipilimumab + Nivolumab | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | Completed | USA | 0 |
| NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
| NCT04109456 | Phase I | BI 853520 + Cobimetinib BI 853520 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Active, not recruiting | USA | AUS | 0 |
| NCT04116320 | Phase I | unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) | Terminated | USA | 0 |
| NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab | Recruiting | USA | 0 |
| NCT04198766 | Phase Ib/II | INBRX-106 INBRX-106 + Pembrolizumab Carboplatin + INBRX-106 + Nab-paclitaxel + Pembrolizumab Pembrolizumab Cisplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium Carboplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 3 |
| NCT04283890 | Phase Ib/II | Melphalan Ipilimumab + Melphalan + Nivolumab | PHP and Immunotherapy in Metastasized UM | Active, not recruiting | NLD | 0 |
| NCT04328844 | Phase I | Roginolisib | A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers | Active, not recruiting | ITA | GBR | 0 |
| NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
| NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |
| NCT04552223 | Phase II | Nivolumab + Relatlimab | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT04589832 | Phase Ib/II | Entrectinib + PAC-1 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Terminated | USA | 0 |
| NCT04720417 | Phase II | Defactinib + RO5126766 | Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Terminated | USA | 0 |
| NCT04879017 | Phase I | FHD-286 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Terminated | USA | NLD | FRA | 0 |
| NCT04935229 | Phase I | Ipilimumab + Nelitolimod + Nivolumab | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | Terminated | USA | 0 |
| NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
| NCT04993677 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Completed | USA | SWE | FRA | ESP | DEU | CAN | 0 |
| NCT05004025 | Phase I | Ipilimumab + Nivolumab | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | Completed | USA | 0 |
| NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
| NCT05077280 | Phase II | Ipilimumab + Nivolumab | A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT05170334 | Phase II | Belinostat + Binimetinib | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT05187884 | Phase II | IDE196 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM) | Active, not recruiting | AUS | 0 |
| NCT05282901 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (PLUME) | Active, not recruiting | FRA | 0 |
| NCT05308901 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naive Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT05315258 | Phase II | Tebentafusp | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) | Active, not recruiting | GBR | 0 |
| NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Completed | NLD | ITA | GBR | BEL | 0 |
| NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Active, not recruiting | USA | NLD | FRA | ESP | DEU | CHE | AUS | 0 |
| NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Withdrawn | 0 | |
| NCT05524935 | Phase II | Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | Recruiting | USA | 0 |
| NCT05542342 | Phase II | Sitravatinib + Tislelizumab | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL) | Completed | ESP | 0 |
| NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Terminated | USA | CAN | 0 |
| NCT05607095 | Phase I | Lifileucel | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT05785754 | Phase I | Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT05907954 | Phase II | IDE196 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Recruiting | USA | NLD | ITA | GBR | FRA | DEU | CAN | AUS | 0 |
| NCT05987332 | Phase II | Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 0 |
| NCT06070012 | Phase II | Tebentafusp | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT06121180 | Phase II | Aflibercept + Cemiplimab | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT06246149 | Phase III | Tebentafusp | Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) | Recruiting | POL | NLD | GBR | FRA | ESP | DEU | BEL | 0 |
| NCT06414590 | Phase II | Tebentafusp | Neoadjuvant Tebentafusp for Uveal Melanoma | Recruiting | USA | 0 |
| NCT06519266 | Phase III | Ipilimumab + Melphalan + Nivolumab Ipilimumab + Nivolumab | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases (SCANDIUM-III) | Recruiting | SWE | 0 |
| NCT06581406 | Phase II | Nivolumab + RP2 Ipilimumab + Nivolumab | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202) | Recruiting | USA | 0 |
| NCT06626516 | Phase Ib/II | Tebentafusp Sargramostim + Tebentafusp Carmustine + Tebentafusp | Tebentafusp-tebn With LDT in Metastatic UM | Recruiting | USA | 0 |
| NCT06627244 | Phase II | Tebentafusp | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT06660420 | Phase I | PRAME-TCR-NK cells Cyclophosphamide + Fludarabine | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | Recruiting | USA | 0 |
| NCT06717126 | Phase II | Roginolisib | A Randomised Phase II Study of Roginolisib in Patients with Advanced/metastatic Uveal Melanoma (OCULE-01) | Recruiting | ITA | GBR | ESP | 0 |
| NCT06805825 | Phase I | NN3201 | A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit | Recruiting | USA | 0 |
| NCT06932757 | Phase II | Quisinostat | Adjuvant Quisinostat in High-Risk Uveal Melanoma | Recruiting | USA | 0 |
| NCT06961357 | Phase Ib/II | Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Recruiting | USA | 0 |
| NCT07015190 | Phase III | IDE196 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | Recruiting | USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 0 |
| NCT07057596 | Phase II | Tebentafusp | Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma (NEO-TB) | Recruiting | ESP | DEU | 0 |
| NCT07063875 | Phase Ib/II | Aldesleukin + Tebentafusp | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression (SILVER) | Recruiting | AUS | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | GBR | AUS | 0 |
| NCT07136181 | Phase Ib/II | NBM-BMX | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM) | Recruiting | USA | 0 |
| NCT07203391 | Phase I | Roginolisib + Tebentafusp | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis (TRIUMPH) | Recruiting | AUS | 0 |